RASSF1 and tuberous sclerosis: Based on these results, it would be interesting to see if tumors from patients with TSC disease that have also lost RASSF1A expression exhibit worse prognosis due to deregulation of the Rheb/RASSF1A signaling pathway and hyperactivation of mTOR.